Antisoma Receives FDA Approval for Oral Fludarabine

19 December 2008 – Antisoma plc today announced that the United States FDA has approved its tablet formulation of fludarabine phosphate (‘oral fludarabine’) as a second-line treatment for chronic lymphocytic leukaemia.

The details can be read here.